Tag: Besponsa for pediatric ALL

Home / Besponsa for pediatric ALL

Categories

Inotuzumab ozogamicin is approved by the USFDA for pediatric patients with acute lymphoblastic leukemia

6th March 2024: Inotuzumab ozogamicin (Besponsa, Pfizer) has been granted approval by the Food and Drug Administration for the treatment of relapsed or refractory CD22-positive B-cell precursor acute...
besponsa-for-pediatric-all

Scan the code